Neutrophil Elastase Selectively Kills Cancer Cells and Reduces Tumorigenesis; Finding May Enable New Direction in Precision Medicine for Cancer

A study published in the June 10, 2021 issue of Cell describes a remarkable new mechanism by which the body's own immune system can eliminate cancer cells without damaging host cells. The findings have the potential to develop first-in-class medicines that are designed to be selective for cancer cells and non-toxic to normal cells and tissues. If successful, this discovery may improve the practice of precision medicine by ensuring the right drug is delivered at the right dose at the right time. The article is titled “"Neutrophil Elastase Selectively Kills Cancer Cells and Attenuates Tumorigenesis.” (Image is of neutrophil).

Login Or Register To Read Full Story